Under construction – not a live service
Sign in
Not yet taking people in FranceNo phase

Skin Bacteria and Skin Fold Rashes in People With Inflammatory Bowel Disease

Follows Staphylococcus aureus bacteria in skin rashes of people with inflammatory bowel disease.

Key facts

Who runs it
Centre Hospitalier Universitaire de Nīmes
Where
Béziers, Millau, Montpellier, and Nîmes, FranceSee the 5 sites
Trial code
Registry title
Intertriginous/Periorificial Dermatoses in Patients With IBD on Anti-TNFα: Relative Abundance of Staphylococcus Aureus Within the Lesion Microbiota and Clinical Correlation (micSPIDER).
Status
Not yet recruiting
People taking part
82 people, planned
Started
Sept 2026
Expected to end
Sept 2029
Type of study
Observational, 2 groups
Record updated
10 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with inflammatory bowel disease who take anti-TNFα medicine and have certain skin lesions in skin folds or around the nose, mouth and scalp (called SPIDER).

Age
From 4 years old. A parent must consent for minors.
Sex
All sexes can join.
Disease stage
Inflammatory bowel disease (IBD) with skin lesions such as crusted rhinitis, inflammatory scalp lesions with hair loss, intertrigo of the large skin folds, or folliculitis (SPIDER).
Earlier treatment
Must be receiving anti-TNFα therapy. Must not have had systemic or topical antibiotics within 1 month before enrolment.

Main reasons for not taking part

  • A change in treatment is planned within 6 months
  • Taking antibiotics (systemic or topical) at enrolment, or within the 1 month before
  • Took part in a clinical drug trial in the last three months
  • Under legal guardianship, conservatorship or trusteeship
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Diagnosed with IBD
  • Receiving anti-TNFα therapy
  • WITH skin lesions such as crusted rhinitis ± inflammatory alopecic scalp lesions ± intertrigo of the large skin folds ± folliculitis (Scalp and Periorificial Inflammatory DERmatis, SPIDER)
  • Parental consent for minor patients
  • Patient who has provided free and informed consent and has signed the consent form
  • Patient affiliated to or beneficiary of a health insurance system

Who cannot take part

  • Patients for whom a change in therapy is planned within 6 months (SPIDER+)
  • Patients receiving antibiotics (systemic or topical) at the time of enrollment, with a window of at least 1 month
  • Patients who have participated in a clinical drug trial within the last three months
  • Patients currently in an exclusion period determined by a previous study
  • Patients under legal guardianship, conservatorship, or trusteeship
  • Patients who refuse to sign the informed consent form
  • Pregnant or breastfeeding patients

Where in France

  • CHU de BéziersBéziers, FranceContact: Louise GUILLON, Dr.No longer taking part
  • Centre Hospitalier de MILLAUMillau, FranceContact: Ariane FIZAZI, Dr.No longer taking part
  • CHU de Montpellier - Hôpital Arnaud de VilleneuveMontpellier, FranceContact: Grégoire LAVAUD, Dr.No longer taking part
  • Montpellier University Hospital, Saint EloiMontpellier, FranceContact: Aurélie DU THANH, Pr.No longer taking part
  • Nîmes University HospitalNîmes, FranceContact: Catherine DUNYACH-REMY, Dr.No longer taking part

About the trial

What the trial wants to find out

The main objective of this study is to evaluate the change in the relative abundance of S. aureus within the lesion-site skin microbiota in SPIDER patients (change between inclusion and 6 months), and to assess whether this change in S. aureus abundance is associated with a favorable (or unfavorable) evolution of the wounds over the same period.

The 2 groups in the trial

  • SPIDER+ group

    Patients diagnosed with IBD receiving anti-TNFα therapy with skin lesions such as crusted rhinitis ± inflammatory alopecic scalp lesions ± intertrigo of the large skin folds ± folliculitis (Scalp and Periorificial Inflammatory DERmatis, SPIDER)

  • SPIDER- group (control group):

    Patients diagnosed with IBD receiving anti-TNFα therapy for more than 1 year, WITHOUT dermatological lesions suggestive of SPIDER

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Inflammatory Skin Diseases of Skin Folds and Perioral Areas (SPIDER) in Patients With Chronic Inflammatory Bowel Disease on Anti-TNFα Therapy: Characterization of the Staphylococcus Aureus Population Within the Lesion Microbiota and Correlation With Clinical Findings
Plain-language title
Skin Bacteria and Skin Fold Rashes in People With Inflammatory Bowel DiseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
10 September 2026